Drug discovery and development in idiopathic pulmonary fibrosis: the changing landscape
Simon Cruwys, Peter Hein, Bob Humphries, Darcey Black
Abstract
Idiopathic pulmonary fibrosis (IPF) is an area of high unmet clinical need and high research activity in the pharmaceutical and biotech industries. The two approved therapies, nintedanib and pirfenidone, have issues with efficacy and tolerability. Despite a considerable number of development programs reaching late-stage Phase 2b or 3 clinical trials, no drug other than nintedanib and pirfenidone has successfully demonstrated a benefit for patients. An analysis of these failures, and consideration of the trajectories of some of the current development projects, may offer novel paradigms for choosing modes-of-action and for the development of successful drugs.
Topics & Concepts
Drug discoveryIdiopathic pulmonary fibrosisDrug developmentMedicinePulmonary fibrosisDrugComputational biologyFibrosisPharmacologyBiologyBioinformaticsInternal medicineLungInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisInhalation and Respiratory Drug DeliveryOccupational exposure and asthma